Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer, MDS Sciex to Partner in Proteomics Tools Development

NEW YORK, May 29 – PerkinElmer and MDS Sciex announced an expanded partnership to develop Time-of-Flight-based mass spectrometry systems, the companies announced on Tuesday.

The joint venture will focus on development of proteomics tools and high-throughput protein processing.

“The MS expertise from MDS Sciex adds a critical element to our existing proteomics and biopharmaceutical platforms,” PerkinElmer CEO Gregory Summe said in a statement. “We believe the PerkinElmer Sciex joint venture will enhance our ability to bring new instrumentation and applications to our pharmaceutical customers.”

The new systems are slated for the market in late 2002, according to the companies. Terms of the partnership were not disclosed.

PerkinElmer and MDS Sciex have engaged in joint ventures since 1986. MDS Sciex also has a joint venture with Applied Biosystems for the supply of mass spectrometer-based products for use in drug discovery and development, according to MDS Sciex.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.